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Abstract: Mesh infection is a major complication of hernia repair. After knitted mesh implantation,
bacteria can grow within textile structures causing infection. In this work, polypropylene (PP) mesh
devices were two-step grafted with hexamethylene diisocyanate (HDI) and β–cyclodexrins (CD)
and then loaded with suitable antimicrobial levofloxacin HCL for hernia mesh-infection prevention.
First, oxygen plasma was able to create surface roughness, then HDI was successfully grafted onto
PP fiber surfaces. Afterwards, CD was covalently grafted onto the HDI treated PP meshes, and
levofloxacin HCL (LVFX) was loaded into the CD cavity of the modified meshes. The modified devices
were evaluated for sustained antibiotic properties and drug-release profiles in a phosphate buffer,
and sustained drug release was observed between interfaces of meshes and aqueous environment.
The antibiotic-loaded PP mesh samples demonstrated sustained antibacterial properties for 7 and
10 days, respectively, against both Gram-negative and Gram-positive bacteria. The CD-captured
levofloxacin HCL showed burst release after 6 h but later exhibited sustained release for the next 48 h.
Among all samples, the modified mesh LVFX-6 was more stable and showed more sustained drug
release and could be employed in future clinical applications.
Keywords: drug release; levofloxacin antimicrobial; β-Cyclodextrin grafting; polypropylene;
hernia repair
1. Introduction
Hernia is a defect due to the rupture or protrusion of an organ at the weakest area of the
human abdominal wall [1,2]. Synthetic meshes have been successfully implanted to reduce hernia
recurrence. Among synthetic meshes, light-weight polypropylene (PP) meshes are most commonly
used to support damaged tissues in operated abdominal wall hernias [3–8]. Nevertheless, a major
complication of PP meshes after hernia repair is the development of infections caused by hernia
repairs [8,9]. The main reasons for mesh infections include gastric perforation and the formation of
fistulas due to the uneven surface topography of knitted meshes. Thus, mesh infection is a major cause
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of hernia failure, and it is difficult to treat it once bacteria biofilm formation develops on the surfaces
of the hernia mesh devices [10–12]. Staphylococcus aureus (SA) is the major pathogenic bacterium
causing severe infections [13].
Infections caused by hernia repairs can be treated using a prophylaxis technique with preoperative
antibiotic treatments before mesh implantation. However, the prophylaxis technique does not work
well on PP mesh materials due to the fact that PP is hydrophobic and does not absorb antibiotics [14,15].
Another way to reduce mesh infection is to supply heavy oral doses of antibiotics. However,
taking such high amounts of antibiotics may cause severe side effects to the body of the patient.
Thus, a controlled and durable antibiotic release system on the mesh materials could be a key technique
to minimize mesh-related infections [16].
β-Cyclodextrins (CD) has been widely used in the preparations of medical devices to provide
sustained antibiotic-release properties [17,18] due to its unique glucose ring structures and multiple
hydroxyl groups with a hydrophobic inside cavity and hydrophilic outside [19,20]. CD can capture
antimicrobial drugs and deliver them slowly for required durations [21]. The hydrophobic cavity
helps CD to capture antimicrobial agents without forming covalent links, and the external hydroxyl
groups can react with a wide range of chemicals such as hexamethylene diisocyanate [22,23]. Moreover,
CD complexes with levofloxacin have been achieved previously [24] and levofloxacin is a promising
antibacterial for wound-infection prevention, which was considered in this research [25].
Surface activation of PP fibers with cold oxygen plasma could be an appropriate surface treatment
method to increase surface roughness and hydrophilicity of PP fibers without damaging their bulk
properties [26] and can increase the reactivity of the PP fibers [27]. Therefore, cold oxygen plasma with
low pressure was proposed to modify PP surfaces for further chemical grafting in this work.
Previously, cyclodextrin (CD)-based hydrogel, comprised of CD and hexamethylene diisocyanate
(HDI), has been used for the preparation of antibacterial-coated polyester (Perietex) mesh for slower
drug release [22]. However, polyester mesh is not suitable for implantation due to its multifilament
braided nature, which results in different abdominal complications such as formation of fistulas,
infection, and other postoperative complications [28].Our research group has previously used
surface-grafted β-Cyclodextrin to capture and release water insoluble compounds such as triclosan in
preparation of antimicrobial mesh materials. Triclosan was used as a model antibacterial to simulate
the antibacterial properties of modified PP meshes. However, due to growing environmental and
human safety concerns, the use of triclosan is limited in the design preparation of medical devices [29].
In this work, we used the antibiotic levofloxacin HCL (LVFX) in the CD-grafted PP mesh materials
for the prevention of mesh infection. Oxygen plasma surface activated PP meshes were grafted with
two-step-grafting HDI and then with CD. Afterwards, levofloxacin HCL was loaded into the grafted
CD, as illustrated in Figure 1. Modified meshes were evaluated using controlled drug release by UV–Vis
spectrophotometer. The antibacterial properties of the levofloxacin-loaded meshes were analyzed
using the agar diffusion test method. Moreover, the characterization of the PP meshes, such as surface
morphology, element analysis, and structural properties of CD-grafted meshes, were investigated
using scanning electron microscope (SEM), Energy Despersive X-ray spectroscopy (EDX), and Fourier
Transform Infrared Spectroscopy (FTIR). The results confirmed the structures and properties of the
PP meshes. Moreover, the levofloxacin loaded PP meshes provided suitable controlled release of the
antibiotics with sustained antibacterial properties for more than one week, which could be used in the
prevention of mesh-related infections.



























Figure 1. Illustrations of experimental design for preparation of antimicrobial PP meshes.
2. Materials and Methods
2.1. Materials
Light-weight (27 g/m2) and large-pore-size (3.5 mm × 2.5 mm) PP mesh was obtained from
Nantong Newtec Textile and Chemical Fiber Co. LTD., Nantong, China. β-Cyclodextrin (CD) (≥97%)
CAS: 7585-39-9 and hexamethylene diisocyanate (HDI) (≥98%) CAS: 822-06-0 was purchased from
Sigma Aldrich, Shanghai, China. N-N dimethylformamide (DMF) Case No. 68-12-12 was purchased
from Ling Feng Company, Shanghai, China. Levofloxacin hydrochloride (98%) was purchased from
Energy Chemicals, Shanghai, China.
2.2. Methods
2.2.1. Surface Functionalization of PP Meshes with Oxygen Plas a
Surface functionalization of PP mesh samples was done by using the low-pre sure cold plasma
treatment. The HD-300 cold plasma machine of radio fr quency (13.56 MHz), power (500 W),
and vacuum (300 cm × 300 cm) treatment chamber was used fo th surface activation of meshes.
All PP mesh devices of equal size (10 cm × 10 cm) were surface modified at opt mized pressure (10 Pa),
power (45 ), and ti e (300 s).
2.2.2. Grafting HDI-CD onto PP Meshes in T o Steps
Oxygen-plasma-treated PP mesh fibers were grafted ith β-Cyclodextrins using a two-step
method. In the first step, the plasma-treated samples were reacted with HDI (2–6%). Afterwards,
the PP-HDI-grafted samples were further reacted with CD (2–8%). A liquor ratio was set (mesh:solution)
as 1:100 for both grafting processes. The maximum temperature and time were 75 ◦C and 60 min,
respectively. fter ard, the surface-grafted PP samples were rinsed with warm distilled water (50 ◦C)
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to remove unreacted CD before drying up. The HDI-modified PP samples were named HDI-2 (2%),
HDI-4 (4%), and HDI-6 (6%), and the CD-modified PP samples were named CD-2 (2%), CD-4 (4%),
CD-6 (6%), and CD-8 (8%) according to the concentrations of HDI and CD in the solutions.
2.2.3. Kinetics of Loading and Release of Levofloxacin HCL
The CD-modified PP samples (0.5 g) were soaked in a 50 mL aqueous solution containing
0.6% (0.3 g) levofloxacin HCL for 24 h. The levofloxacin HCL loaded samples were dried at 40 ◦C
and named as LVFX-2, LVFX-4, LVFX-6, and LVFX-8, according to the different CD-grafted PP
samples, respectively.
Moreover, the drug-release characteristics of the levofloxacin-HCL-loaded samples (LFVX–2 and
LVFX-6) were measured to simulate their drug-release profiles. Meshes of 2 cm square were cut from
LVFX-2 and LVFX-6. Samples were put in a centrifuge tube containing 8 mL PBS, and the mixtures
were shaken at 70 rpm at 37 ◦C for the required durations. A buffer solution was prepared using
disodium hydrogen phosphate dodecahydrate and sodium dihydrogen phosphate dihydrate. During
absorption measurements, 1 mL of the mixture solution of each sample was extracted and a fresh 1 mL
of buffer solution was added to the centrifugal tube. Absorption measurements were conducted using
UV–Vis spectrophotometer (TU-1901 Beijing Purkinjie Co., Ltd., Beijing, China). Absorptions of all
samples at 290 nm were measured. The accumulative drug-release rate (%) was determined as the
ratio of released drug to the drug loaded onto the samples. Absorption values were recorded as the
average values to calculate drug release (%).
3. Characterization
3.1. SEM and EDX
The modified and untreated samples were coated (E–1045, Hitachi, Tokyo, Japan) with platinum
(Pt) before testing on scanning electron microscope (SEM) by (Quanta 250, FEITM, Hillsboro, OR, USA).
However, for element analysis, an Energy Dispersive X-ray spectroscopy (EDX) oxford instrument
unit (ISIS 300, Oxfordshire, UK) was connected with the SEM.
3.2. FTIR
All modified and control samples were analyzed using a Fourier Transform Infrared Spectroscopy
(FTIR) Attenuated Total Reflection mode (ATR) (Nicolet 6700, Waltham, MA, USA). Samples were
tested in the range of wave numbers 500–4000 cm−1 with resolution of 4.0 cm−1.
3.3. Antibacterial Activity Assessment
A qualitative analysis of antibacterial properties was assessed using an agar-diffusion test method,
described in a recently published article [29]. A bacterial suspension of 400 µL (1 × 108 CFU/mL) was
evenly spread on agar plates using sterilized swabs. Escherichia coli ATCC25922 and Staphylococcus
aureus ATCC 25923 (Shanghai, China) were selected for antibacterial activity of the modified meshes.
All modified and control samples in the size of 1 cm × 1 cm square were placed on agar plates
containing a suspension of bacteria. The agar plates containing the suspension and samples were
incubated in an oven at 37 ◦C for 24 h. Afterward, the zone of inhibition was measured in four
directions using a digital vernier caliper and reported as an average value. The following formula was
used to calculate zone of inhibition:
A = (B − D)/2 (1)
where A = zone of inhibition, B = inhibition zone measured after incubation showing antibacterial
activity, and D = inhibition zone before incubation.
Moreover, a serial plate-transfer test with agar plates was performed to confirm antibiotic
release properties of the modified meshes. The objective of this test was to evaluate the antibacterial
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properties of the CD-grafted samples with reference to the antibacterial release time in days.
The objective of the serial plate test was to evaluate release performance of levofloxacin according
to the number of days. An agar plate with fresh bacteria suspension was changed after every
24 h, and samples were transferred onto a new agar plate containing equal colony-forming units
(1 × 108 CFU/mL) of Escherichia coli ATCC25922 or Staphylococcus aureus ATCC 25923, respectively.
The serial plate-transfer test was continued until the antibacterial properties of the modified meshes
were perceived.
4. Results and Discussion
4.1. Cyclodextrin Grafting and Levofloxacin HCL Loading
As shown in Figure 2, CD was grafted onto PP meshes using two-step reactions. Oxygen plasma
was able to activate PP meshes to create hydrophilic structures on the surfaces. Then, two grafting steps
were carried out. In the first step (Figure 2a), HDI was successfully reacted with the plasma-treated
meshes, and in the second step, the HDI-grafted PP mesh devices were further reacted with CD
(Figure 2b). Thus, the grafted CD on the PP forms complexes with levofloxacin HCL. Afterward,





















75  °C,  respectively. Moreover, Figure  3  shows  the weight‐percentage  increases of HDI, CD,  and 
levofloxacin on the PP meshes, respectively. HDI‐6 (6%) demonstrated better weight increases than 
Figure 2. Two-step grafting (a) PP-HDI grafting (b) PP-HDI-CD grafting and (c) levofloxacin-loaded
PP meshes.
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The reaction time and temperature of the process were optimized and achieved at 60 min and
75 ◦C, respectively. Moreover, Figure 3 shows the weight-percentage increases of HDI, CD, and
levofloxacin on the PP meshes, respectively. HDI-6 (6%) demonstrated better weight increases than
others, and a thin layer of HDI coating was achieved on PP fibers. The corresponding weights of all
plasma-treated meshes increased. However, the HDI-grafted meshes were immediately transferred to
the CD solution without washing. Therefore, we were unable to measure the real weight increases of
the HDI-grafted samples. All CD-incorporated samples were connected to the same concentration
of HDI. Thus, the average weight increase of CDs for CD-2, CD-4, CD-6, and CD-8 were 5.128%,
6.40%, 7.271%, and 7.171%, respectively. However, after levofloxacin HCL loading, the average weight
increases of LVFX-2, LVFX-4, LVFX-6, and LVFX-8 were 1.025%, 2.29%, 1.614%, and 1.60%, respectively.
LVFX-6 had a greater weight increase compared with all other CD-grafted and levofloxacin-loaded
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Figure 3. Weight-increase percentage of HDI, CD, and LVFX loaded samples. Data of each sample
expressed as averages (n = 3).
4.2. Surface Morphology of PP Meshes
SEM images of the PP mesh samples are shown in Figure 4. The surfaces of the PP control before
oxygen-plasma functionalization (Figure 4a,b) were very smooth. Nevertheless, after oxygen-plasma
modification (Figure 4c,d), the PP mesh surfaces were slightly rougher. The meshes that were
oxygen-plasma treated and grafted with HDI (Figure 4e,f) displayed a layer of HDI coating on
the surfaces of the PP meshes. Additionally, the surfaces of the CD-grafted mesh samples can be
observed (Figure 4g,h), which shows small beads and hills connected with spherical round-shaped
fibers. It can be seen that (Figure 4i,j) after levofloxacin-loading, the CD-grafted meshes displayed
similar results but with a little more swelling of the CD grafting onto the PP mesh fibers, showing that
levofloxacin HCL loading has no effect on the structure of the fibers.






The results of  the SEM  images demonstrated  that  the surface grafting of HDI and CD on PP 
fibers was  successful,  confirming  that  low‐pressure  cold  oxygen  plasma  is  a  suitable  process  to 
effectively incorporate CD onto PP meshes. 
4.3. Characterization of HDI, CD Grafting, and Levofloxacin‐Loaded Modified PP Mesh 
Element analysis of untreated and  surface‐modified meshes was  (Figure 5)  conducted using 
Energy Dispersive X‐ray spectroscopy (EDX). 
Figure 4. SEM images of: (a,b) PP control; (c,d) oxygen-plasma treated; (e,f) HDI-grafted HDI-6 (g,h)
CD-grafted CD-6; and (i,j) levofloxacin-loaded (LVFX-6) (top row 500×, bottom row 1000×).
The results of the SEM images demonstrated that the surface grafting of HDI and CD on PP fibers
was successful, confirming that low-pressure cold oxygen plasma is a suitable process to effectively
incorporate CD onto PP meshes.
4.3. Characterization of HDI, CD Grafting, and Levofloxacin-Loaded Modified PP Mesh
Element analysis of untreated and surface-modified meshes was (Figure 5) conducted using
Energy Dispersive X-ray spectroscopy (EDX).
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Figure 5. E spectra and ele ent eight percentage (a) PP control; (b) oxygen-plas a treated (c)
I-grafted I-6 (d) -grafted and levofloxacin-loaded L FX-6.
It can be observe that the ntreate control esh (Fig re 5a) sa ple isplaye the presence
of a carbon ( ) ato ithin 0.5 ke . o ever, the las a-treate esh fibers sho e carbon ( )
an oxygen ( ) ato s (Figure 5b) ithin 0.5 ke , hich confir e the o ification of PP fibers ith
oxygen plas a. oreover, Figure 5c shows one extra peak of nitrogen (N) on the modified PP, as well as
oxygen (O) atom weight increase from 3.32% to 13.76%. All three peaks are within 0.5 keV, confirming
the existence of HDI on the PP fiber surfaces. Moreover, cyclodextrins-grafted and levofloxacin-loaded
LVFX-6 showed the existence of the same three elements—carbon (C), oxygen (O), and nitrogen
(N)—at the same position within 0.5 keV but with slightly different peak heights. Furthermore,
an additional peak of fluorine (F) atom showed up at 0.8 keV (Figure 5d), which confirmed the loading
of levofloxacin HCL into the CD cavity. These results of the element analysis are in agreement with
a recently published paper, except for the presence of the fluorine atom [29].
FTI spectra of PP control, I, and -grafted esh sa ples at different reaction stages ere
observed (Figure 6). The untreated PP showed absorbance bands at 2950 cm−1, 2916 cm−1, 1452 c − ,
and 1376 c −1 for (va CH3), (va CH2), (δCH3), and (δCH3), respectively [30,31]. It can be observed
that plasma-treated meshes showed absorbance bands at 3322 cm−1 (Figure 6a), and OH groups on
the PP fibers were detected due to the surface activation with oxygen plasma. However, all other HDI-
and CD-grafted samples displayed more absorbance peaks (Figure 6b) at 3322 cm−1, 1620 cm−1, and
1576 cm−1, showing hydroxyl (OH), amide I (ν C=O), and amide II (δNH) formations, respectively.
It can be observed that the CD-grafted mesh samples maintained all peaks of HDI-grafted meshes and
also showed absorbance peaks at 1701 cm−1 and 1254 cm−1 due to the formation of carbonyl groups
(ν C=O) and C–H (ν CH), respectively. However, an absorbance peak at 1030 cm−1 was observed,
which shows the C–O group of CD, and is consistent with the literature [29,32]. The absorbance bands
of amide I at 1620 cm−1 and amide II at 1576 cm−1 confirmed CD-grafted samples and the formation
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of urethane, consistent with the literature as well [20,22]. Moreover, we did not find any absorbance
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Figure 6. FTIR (ATR) spectra of; (a) PP control and oxygen-treated PP fibers (b) PP control, HDI-grafted,
CD-grafted CD-6, and levofloxacin-loaded LVFX.
4.4. Antibacterial Activity of odified PP eshes
The antibacterial performance of PP control and modified meshes was evaluated using an
agar-diffusion test method as a qualitative analysis. Figure 7 shows control PP and the modified LVFX-2
and L FX-6 meshes samples. The PP control and CD-grafted without levofloxacin HCL mesh sa ples
did not show any antibacterial activity. However, the PP-grafted and levofloxacin-HCL-loaded mesh
samples displayed suitable inhibition-zone diameters. The LVFX-2 showed average inhibition-zone
diameters of 5.3 m and 5.7 mm for S. aureus and E. coli, respectively. LVFX-6 showed increased
inhibition-zone diameters of 6.7 mm and 6.9 mm for S. aureus and E. coli, respectively.
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Figure 7. Antibacterial activity (a,b) PP control without modification, (c,d) LVFX-2, (e,f) LVFX-6,
Top row S. aureus and bottom row E. coli.
Moreover, LVFX-2 and LVFX-6 (Figure 8) samples were further analyzed using sustained
agar-diffusion tests to examine their durable antibacterial performance over the course of several days.
These tests showed the antibacterial activity of the samples with the release of antibacterial agents after
each 24-h period. LVFX-2 showed average inhibition zone and sustained-release antibiotic properties
for 7 days against E. coli and S. aureus. However, LVFX-6 was more stable and showed an average
inhibition zone with the release of antibacterial functions for 10 days against both types of bacteria.
It can be observed (Figure 8a) that LVFX-2 showed slightly different inhibition zones for S. aureus and
E. coli. During all 7 days, E. coli showed greater inhibition-zone diameter than S. aureus. Furthermore,
the inhibition zone for both types of bacteria was reduced by more than 50% in first 3 days. The average
minimum inhibition zone for S. aureus and E. coli was 0.6 mm and 0.8 mm, respectively. In the case of
LVFX-6, the inhibition-zone diameter (Figure 8b) for both types of bacteria were almost similar and
showed antibacterial properties for 10 days. Overall, the inhibition of E. coli by the meshes was always
better than that of S. aureus. Interestingly, inhibition-zone diameters for the 6th, 8th, and 10th days for
both bacteria were similar and inhibition-zone diameters gradually reduced for both types of bacteria
(S. aureus and E. coli).
Previously, PP meshes have been surface modified with silver nanoclusters as an antimicrobial
to prevent hernia-mesh infection [33]. Moreover, antibiotic-loaded polyester mesh has been tested
using AATCC 100–2004 [34]. Since then, polyester mesh has been restricted in its use for hernia repair
due to the formation of fistulae and other abdominal complications. Further, certain antibacterial
methods may not be suitable for mesh-infection prevention. PP hernia mesh infection is a serious
problem for hernia operations, and it may require antibacterial remedies for at least more than one
week. Here, the CD-loaded antibiotics could be a good option for preventing mesh infection.
Recently, this group has conducted the surface modification and coating of CD by incorporating
triclosan as a model antibacterial agent and hydrophobic agent to simulate a slow-releasing pattern.
Sustained antibacterial activity was achieved for up to 7 days [35]. Improvement of the process with
a two-step grafting method of HDI and CD was able to improve the antibacterial activity to more
than 10 days [29]. However, triclosan cannot be used as an antibacterial agent for hernia repair due
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to restrictions and growing environmental concerns for human safety. However, the antibiotic agent
levofloxacin HCL has shown desirable antibacterial performance for 10 days. Thus, a PP surface















Figure 8. Sustained efficacy test performance (a) LVFX-2, and (b) LVFX-6. (n = 3).
4.5. Release Kinetics of Levofloxacin HCL
Figure 9 displays the slow release of levofloxacin-HCL-loaded samples LVFX-2 and CD-LVFX-6.
It can be seen that both samples continuously released drugs for 48 h. Nevertheless, in first 6 h,
a considerable amount of the levofloxacin HCL was released. However, the drug release was somewhat
stable after 9 h, and after 12 h, the release was more stable. It can be seen that 12–48 h sustained release
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of drug was observed. However, LVFX-2 released 76% of the drug in first 12 h and a total 83.5% of
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Figure 9. Drug release analysis of levofloxacin-loaded LVFX-2 and levofloxacin-loaded LVFX-6.
However, LVFX-6 released accumulative levofloxacin HCL of 70% in first 12 h and later up to 77%
drug was released in 48 h. After 1 h, both samples of LVFX-2 and LVFX-6 released 34.6% and 28.8%,
respectively, of the total drug amount, which was a greater amount than any hour during the first
48 h. This may be due to the fact that levofloxacin HCL was adhered to the surfaces of grafted CD
and other inclusion complexes with CD. Therefore, CD-grafted samples displayed a burst release of
levofloxacin HCL initially and showed sustained release after 12 h. Moreover, among both samples,
LVFX-6 showed more stable and sustained drug release compared to LVFX-2. We also noticed the
same trend of drug release for antibacterial properties. Therefore, it is confirmed that levofloxacin
HCL is initially released in large amounts and then it reduces to a sustained release as time increases.
Moreover, the burst release of antibiotics in the initial stage followed by sustained release could
be an advantage for mesh-infection prevention due to the fact that after hernia repair, bacteria grow in
the initial stage after surgery. Thus, such behavior of antibiotic release could be more suitable to cure
mesh infection [36].
5. Conclusions
The CD-grafted PP meshes captured levofloxacin HCL and showed excellent antibacterial
properties for 10 days. The low-pressure cold oxygen plasma effectively modified the inert PP meshes.
HDI was successfully grafted onto oxygen–plasma-treated meshes. Moreover, CD was connected and
formed covalent bonding with HDI and PP mesh fibers and loaded levofloxacin HCL. The modified
PP mesh devices demonstrated suitable antibacterial properties and sustained drug-release kinetics.
It was found that CD-grafted PP meshes loaded with levofloxacin demonstrated burst release of the
drug during the first few hours but later showed sustained drug release. Thus, the yield product could
be suitable for mesh-infection prevention.
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